Thiago Carvalho on Nostr: 'The T-cell engager teclistamab acts on T cells through CD3 (the defining marker of T ...
'The T-cell engager teclistamab acts on T cells through CD3 (the defining marker of T cells) and targets plasmablasts and plasma cells through BCMA. Teclistamab has been shown to be highly effective in patients with multiple myeloma.4 Thus, we hypothesized that teclistamab may be effective for targeting severe autoimmune diseases, even after failure of conventional B-cell depletion.'
#Immunology #Immunotherapy #Autoimmunity
https://www.nejm.org/doi/full/10.1056/NEJMc2408786Published at
2024-09-07 08:36:00Event JSON
{
"id": "5ade72bbd3f41bf3e9bff5265ecd4c495db694243001c88090147edcc0ee4dd7",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1725698160,
"kind": 1,
"tags": [
[
"t",
"immunology"
],
[
"t",
"immunotherapy"
],
[
"t",
"autoimmunity"
],
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/113095354643470486",
"activitypub"
]
],
"content": "'The T-cell engager teclistamab acts on T cells through CD3 (the defining marker of T cells) and targets plasmablasts and plasma cells through BCMA. Teclistamab has been shown to be highly effective in patients with multiple myeloma.4 Thus, we hypothesized that teclistamab may be effective for targeting severe autoimmune diseases, even after failure of conventional B-cell depletion.'\n#Immunology #Immunotherapy #Autoimmunity\nhttps://www.nejm.org/doi/full/10.1056/NEJMc2408786",
"sig": "81d60466c8e485caa8af43088d885dfa266a7847aba39d45a936f98393efbb5a5789984be3ef5ab6b093e085167d36b0e20a726d161557db0f22c40e97bef524"
}
